Partnership aims to reduce over-treatment of prostate cancer by identifying
and validating biomarkers of high-risk prostate cancer
SAN JOSE, Calif., and ROCKVILLE, Md., May 1 /PRNewswire/ -- The Canary Foundation, a nonprofit organization that funds research in early cancer detection, and the National Cancer Institute's Early Detection Research Network (EDRN), jointly announced today that the two organizations are forming a partnership for the purpose of identifying and validating biomarkers of high-risk prostate cancer within the context of an active surveillance study. Six of the nation's leading medical research institutions will be participating in this study, which will be ready to enroll patients this summer.
In the United States, prostate cancer is the most commonly diagnosed cancer among men and is the second leading cause of cancer deaths among men. The American Cancer Society estimates that in 2008, 186,320 men will be diagnosed with prostate cancer in the United States and 28,660 will die from it. Diagnosis and treatment of prostate cancer has its challenges. Many cases of prostate cancer would not have been lethal if left untreated, yet we are currently unable to accurately predict which cases can be safely left untreated. Consequently, over-treatment has become a major problem among men with early prostate cancer and many thousands of men each year undergo excessive treatments such as surgery and are not helped by it. Better methods of detecting prostate cancers early are also needed as many cases of lethal prostate cancer are still missed by current screening strategies.
With a joint goal of reducing over-treatment by identifying aggressive
versus passive tumors, the Canary Foundation and the EDRN are combining
resources and efforts. The Canary Foundation will provide funding related
to initiating a Prostate Active Surveillance Study (PASS) at six
institutions across the country. To expedite the storage and processi
'/>"/>
| SOURCE Canary Foundation Copyright©2008 PR Newswire. All rights reserved |